CATEGORY : Biomarkers

Life Science Market Reports

Our life science market intelligence products have been recognized by market insiders and outsiders alike for their accuracy, in-depth analysis, and unique insights.

Market Reports

Evolution in the precision oncology landscape – Part 2 (Therapeutic Developments)

Over the past several months, we spoke to experts across the precision medicine landscape to understand some of the key changes and most impactful scenarios they expect in this space.

Spatial Omics Year in Review

2019 was a big year for the spatial omics market—we saw a number of long-awaited commercial launches and new product offerings, among other exciting news in the field. This blog

Select 2019 Trends and Discussions

  Los Angeles, CA January 3, 2019 – The end the last decade deepened my personal belief that the personalized medicine revolution will be driven by tools and diagnostics, rather

Oncology Cell Therapy Companies Race to the Finish Line

Tracking the Oncology Cell Therapy Space Cell therapies is a rapidly growing space with huge potential to improve oncology patient outcomes. As examples, the two approved CAR-T products Yescarta (Kite/Gilead)

Evolution in The Precision Oncology Landscape – Part 1 (Diagnostics Developments)

Over the past several months, we spoke to experts across the precision medicine landscape to understand some of the key changes and most impactful scenarios they expect in this space.

Pain Points, Unmet Needs, and Disruption in Precision Medicine – Part 1

DeciBio’s mission is to provide market intelligence and strategic insights that drive disruption and innovation in the precision medicine and life science industry. To this end, my colleague, Colin Enderlein,

ASHG 2019: DeciBio Highlights

We just returned from ASHG 2019 in Houston and while the city provided a lot of excitement with the Astro’s headed to the World Series, the meeting itself lacked any

I/O Biomarker Spotlight: Digital Pathology and Multiplex Spatial Tissue Analysis

We’ve noticed a trend in the oncology biomarker this year.  Both anecdotally, through our observations and discussions at AGBT and AACR and with our network of industry KOLs, and analytically,